PRESS RELEASES
The Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) publishes the preliminary results of its Annual Report on Access to Orphan Drugs in Spain 2022 in which it analyzes the access situation of trade-name products with orphan designation in force as of December 31, 2022.
At the end of the year, 146 orphan drugs had been authorized for marketing in the EU, of which 123 have already reached Spain (84%) but only 63 (43%) are financed.
During 2022, the SNS has incorporated 9 new orphan treatments and the average time from obtaining the National Code to its funding has been 34 months.